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Abstract
Background: People with Multiple Sclerosis (pwMS) often experience a disturbed gait function such as foot-drop. The
objective of this pilot study was to investigate the medium term effects of using Functional Electrical Stimulation (FES) to
treat foot-drop over a period 12 weeks on gait and patient reported outcomes of pwMS.
Methods and Findings: Nine pwMS aged 35 to 64 (2 males, 7 females) were assessed on four occasions; four weeks before
baseline, at baseline and after six weeks and twelve weeks of FES use. Joint kinematics and performance on the 10 meter
and 2 minute walk tests (10WT, 2 minWT) were assessed with and without FES. Participants also completed the MS walking
Scale (MSWS), MS impact scale (MSIS29), Fatigue Severity Score (FSS) and wore an activity monitor for seven days after each
assessment. Compared to unassisted walking, FES resulted in statistically significant improvements in peak dorsiflexion in
swing (p = 0.006), 10MWT (p= 0.006) and 2 minWT (p = 0.002). Effect sizes for the training effect, defined as the change from
unassisted walking at baseline to that at 12 weeks, indicated improved ankle angle at initial contact (2.6u, 95% CI 21u to 4u,
d = 0.78), and a decrease in perceived exertion over the 2 min walking tests (21.2 points, 95% CI 25.7 to 3.4, d =20.86).
Five participants exceeded the Minimally Detectable Change (MDC) for a training effect on the 10mWT, but only two did so
for the 2 minWT. No effects of the use of FES for 12 weeks were found for MSWS, MSIS29, FSS or step count.
Conclusion: Although FES to treat foot-drop appears to offer the potential for a medium term training effect on ankle
kinematics and walking speed, this was not reflected in the patient reported outcomes. This observed lack of relationship
between objective walking performance and patient reported outcomes warrants further investigation.
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Introduction
Multiple Sclerosis (MS) is a progressive autoimmune disease of
the central nervous system. Although symptom manifestation can
vary considerably among individuals, the cluster of symptoms
comprising fatigue [1], weakness, posture and movement distur-
bances is common [2]. Heesen et al [3] reported that gait function
was most frequently rated as the most important domain by people
with MS (pwMS). A common gait problem even in minimally
impaired pwMS is decreased dorsiflexion in the swing phase of the
gait cycle, i.e. the phase when the foot is not in contact with the
ground [4–6]. This means that the toe drags or is close to the
ground during the swing phase (i.e. foot-drop), which increases the
risk of tripping, stumbling and falling. A recent cohort study [7]
reported that 150 people with a confirmed diagnosis of MS
reported 675 falls and 3785 near falls over a period of three
months, 11% of the falls resulted in injury. First-line treatment for
foot-drop is usually physiotherapy or the use of an ankle foot
orthotic device (AFO) [8]. However, increasingly, Functional
Electrical Stimulation (FES) to the pre-tibial muscles, to aid
dorsiflexion in swing, is also prescribed. Although FES for people
with a stroke has received considerable attention [8], it is only
relatively recently that the effects of FES to treat foot-drop have
been investigated in pwMS. Studies including pwMS have
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indicated a direct orthotic effect, defined as the difference between
the conditions without and with the assistance of FES recorded at
the same assessment, both in new and established users [6,9,13] of
FES. Direct orthotic effects included an increase in walking speed
both over a shorter distance such as the 10 meter walk test
[6,9,11–13] and longer duration walking tasks such as the
4 minute figure of eight walking test [9] and 5 minute walk test
[10]. In a preliminary trial with new users of FES, Scheffler [14]
did not find a statistically significant effect of FES for the timed
5 m level walk tests over different surfaces and the Timed Up and
Go test, but the performance on the stair ascent and descent test
was significantly improved with the assistance of FES. Interest-
ingly, ten out of the11 participants in this study preferred FES over
no device and 9 out of the 11 preferred FES over using an AFO.
In a qualitative study, Bulley et al [15] reported a similar
preference (8 out of the 9) for FES over AFO in stroke patients.
A possible therapeutic or training effect of FES, i.e. an
improvement in the person’s gait without the assistance of FES
over time, as opposed to a direct orthotic effect of FES as assessed
within a single session, is addressed in longer term studies.
Although a few studies have investigated the medium-term and
long-term effects of FES to treat foot-drop in pwMS [9,11,12,16],
these studies only reported walking speed in the 10 m walk test or
in 3 or 4 minute walking tests and did not assess patient reported
walking-related outcomes or measures of participation and fatigue.
Only two studies have reported the effect of FES to treat foot-drop
on self-reported measures in pwMS. Esnouf et al. [17] reported a
significant increase in both the satisfaction and performance
components of the Canadian Occupational Performance Measure
in the FES group compared to an exercise group after a period of
18 weeks of FES. Recently, Taylor et al [13] found statistically
significant improvements in both the psychological and physio-
logical components of the MSIS29 after 6 weeks of using FES for
foot-drop. However, to our knowledge, there are no studies
addressing the medium term effects of FES on important patient-
reported outcomes such as walking performance and fatigue or on
daily physical activity in pwMS who have been newly prescribed
FES treatment. Furthermore, the mechanisms underpinning
possible improvements in walking speed after more prolonged
use of FES to treat foot-drop, such as the gait kinematics, have not
been fully explored.
Therefore, the aim of this study was to investigate the effects of
12 weeks of FES use on gait kinematics and walking performance
(primary outcome measures), patient reported outcomes and
habitual physical activity (secondary outcome measures) of pwMS
who had been newly prescribed this treatment. We hypothesised
that a 12 week period of FES use would shift the gait kinematics,
both with and without the assistance of FES, closer towards more
normal values which would result in improved walking perfor-
mance and, in turn, might plausibly be associated with improve-
ment in important patient-reported outcomes of walking perfor-
mance and impact of MS on daily life. Based on the findings by
Taylor et al [11], it was also hypothesized that using FES would
reduce the effort of walking and that this would result in a decrease
of self-reported fatigue.
Methods
The protocol for this trial and supporting checklist are available
as supporting information; see Checklist S1 and Protocol S1.
Ethics Statement and trial registration
The study was approved by both Queen Margaret University
and National Health Service (NHS) research ethics committees
(South-East Scotland Research Ethics Committee, reference
number 11-AL-0229, see ‘Approval Letter S1) and the NHS
research and development office. In accordance with the
declaration of Helsinki, all participants provided written informed
consent before taking part in the study. The authors confirm that
all ongoing and related trials for this intervention are registered
with Clinical Trials.gov (NCT01977287).
Participants
Participants were recruited through a community NHS
(National Health Service) physiotherapy service in Edinburgh,
UK. People with a clinical diagnosis of MS as defined using the
2005 McDonald Criteria [18] between the ages of 18 and 75 who
were considered by a clinical specialist physiotherapist to be
suitable for FES to counter dropped foot were eligible for
participation in this study. To assess whether a patient was an
appropriate candidate for FES, the physiotherapist carried out a
comprehensive physical examination. The examination involved
the assessment of active and passive range of movement at the
ankle with the hip and knee in a flexed and an extended position
which provided an indication of muscle weakness and any muscle
shortening. Patients who did not have the strength in the affected
leg to bend the hip and knee off the couch and hold the weight of
the lower limb against gravity when tested in supine lying were
considered unsuitable for FES. Also patients in whom walking
distances had become extremely limited and were not community
walkers were rarely considered suitable. Muscle tone in the
gastrocnemius was assessed by moving the ankle passively and
attempting to elicit clonus at the ankle when applying a quick
stretch. Patients who did not have a plantargrade range of motion
at the ankle and had a fixed deformity were considered to be
unsuitable for FES.
Those eligible for participation were provided with a Participant
Information Sheet and a study invitation letter. Those agreeing to
take part visited the gait analysis laboratory at Queen Margaret
University, Edinburgh on four occasions, four weeks before the
baseline assessment (no FES) and with and without the assistance
of FES at baseline and after 6 and 12 weeks of regular device use,
which they commenced after the baseline assessment.
At each visit participants underwent a 3D gait analysis
assessment; a 10-metre timed walking test and a two-minute walk
test, all with and without FES. All 3D gait analysis assessments
were carried out without the assistance of FES first, followed by
with FES for each assessment visit. The 10 meter and two minute
walk tests were performed without the assistance of FES first,
followed by same walk tests with the assistance of FES at the
baseline and 12 week assessment. At the 6 week assessment, the
10 meter and two minute walk tests were performed with the
assistance of FES first and then without FES.
Participants sat down to recover for 5 minutes between each of
the tests. Participants were able to use additional walking aids
during testing if required. However, if they commenced testing
with a walking aid, all further assessments were conducted using
the same aid.
Walking Performance Tests
Participants were asked to walk parallel to a straight corridor
wall for ten metres at their preferred walking speed in accordance
with Rossier and Wade [19]. The time taken to walk 10 meters
was recorded by a stopwatch. The test was repeated and the
average was taken for analysis. Participants were also asked to walk
continuously around a 16.5 m elliptical course for two minutes
[20]. The distance travelled during the two minutes was recorded.
In a recent study within-day reliability for the 10 meter and
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2 minute walk tests for community walkers with MS was reported
between 1.7–2.7 s and 16–22 m respectively [21].
During the first lap and immediately after the test, participants
were asked to rate their rate of perceived exertion (RPE) on the
Borg Scale [22] where 6 is ‘no exertion at all’ and 20 ‘maximal
exertion’. The difference between the RPE immediately after the
test and the RPE in the first lap (dRPE) was used for analysis.
Gait Analysis
Three dimensional gait analysis was undertaken using a 100 Hz
eight infra-red camera Vicon Nexus three dimensional (3D)
motion analysis system (Vicon Motion Systems, Oxford, UK).
Participants had 14 mm diameter passive reflective sphere makers
attached to anatomical landmarks of their lower limbs and the
pelvis according to the Vicon Plug-In-Gait manual which is based
on the Helen Hays marker system [23]. A static trial was
conducted using a Knee Alignment Device (KAD) to derive the
orientation of the knee flexion-extension axis. The KADs were
removed and standard 14 mm reflective markers were attached
over the lateral epicondyle of each femur for the walking trials.
Each participant performed six trials of approximately five meters
for each condition (with and without FES). For the gait analysis
trials only, participants walked barefoot with the FES footswitch
taped underneath the heel. Ankle angle at initial contact, peak
dorsiflexion in swing, peak knee flexion in swing, hip range of
motion over the gait cycle and stride length of the stimulated leg
were derived for each trial and then averaged for each participant
for analysis.
Step count
Objective measurement of habitual physical activity was
recorded by an ActivPAL activity monitor. After each assessment
visit, participants were asked to attach the lightweight monitor to
one of their legs (anterior thigh) using adhesive gel stickers
(Palstickies) and wear this for a period of seven days before
returning it to the researcher. The activity monitor records daily
step count and the time spent sitting or lying, standing and walking
(‘stepping’).and the sit to stand transitions. Standard Error of
Measurement for step count for walking at a speed of 3.2 km/h on
a treadmill and for self-selected overground walking for healthy
individuals has been reported as 6 and 22 steps respectively [24].
Only step count averaged over at least 5 days was derived for
analysis in this report.
Self-reported measures
At the end of each visit participants were given a questionnaire
booklet including the MS Impact Scale-29 [25], the Fatigue
Severity Score [26] and the MS walking scale [27] to complete at
home and return with the activity monitor in an addressed
stamped envelope to the researcher.
The Multiple Sclerosis Impact Scale-29 (MSIS-29) is an
instrument measuring the physical (20 items) and psychological
(nine items) impact of Multiple Sclerosis. Participants were asked
to circle one number which best described the impact of MS on
their day-to-day life during the last two weeks. The numbers range
from ‘1’ (not at all) to ‘5’ (extremely). The total score was
calculated by summing the answers to the 29 questions and hence
ranged from 29 to 145. Responsiviness for the MSIS-29 has been
reported as good, with effect sizes of 0.82 and 0.66 for the physical
and psychological scale respectively [25].
The Fatigue Severity Scale [26] consists of nine statements
regarding fatigue during the past week. Participants were asked to
circle one number between 1 and 7, a low number indicating the
statement is not very appropriate and a high value indicating full
agreement with the statement. The average of the numbers
selected for each of the nine questions is the final score. A higher
score indicates a higher impact of fatigue. Learmonth et al [28]
reported acceptable reliability of the FSS over six months
(ICC=0.751).
The MS walking scale (MSWS2v1 [27]) consists of 12 items
regarding the perceived walking performance over the last two
weeks. Walking limitations are self-reported using five response
categories generating a total transformed score ranging from 0 to
100, with lower scores indicate better mobility. Excellent reliability
of six months (ICC=0.927) has been reported for the MSWS12v1
with a SEM of 8 and MDC of 22 points [27].
Functional Electrical Stimulation
The single channel Odstock Drop Foot Stimulator (ODFS III)
or the newer version, the Pace (both Biomedical Engineering and
Medical Physics, Salisbury, UK) were used to administer FES.
Stimulators were fitted and set-up by the physiotherapist and these
settings were not changed before or during the assessments. The
intensity of the current amplitude ranged from 20 to 70 mA and
was determined by the amplitude required to achieve adequate
dorsiflexion of the ankle to achieve foot clearance during the swing
phase of the gait as decided by a physiotherapist qualified to fit the
ODFSIII and Pace. In the majority of patients, standard set-up
was used whereby one square 50650 mm gel surface electrode
(PALS, Platinum Blue, Nidd Valley Medical Ltd, Knaresborough
Ltd) was placed over the common peroneal nerve as it passes over
the head of the fibula and another over the motor point of the
Tibialis Anterior. However, in some patients adjustments were
required to the positioning or the polarity of the electrodes to
produce the desired effect.
Data analysis
Using the terminology by Taylor et al [12], the following effects
of FES use over 12 weeks were assessed in this study. The training
effect on the gait kinematics and walking performance tests was
defined as the change in gait kinematics and walking performance
without FES at 12 weeks relative to the gait kinematics and
walking performance without FES at baseline. The direct orthotic
effect is the difference in walking outcomes between walking with
and without FES at the same assessment, at baseline and the 6
week and 12 week assessments. Finally, the combined effect of the
training and direct orthotic effect is defined as the total orthotic
effect, i.e. the change in walking outcomes at 12 weeks with the
assistance of FES relative to the walking outcomes at baseline
without FES.
A doubly repeated measures ANOVA with two within-subject
factors of time (three levels; baseline, 6 weeks post-baseline, 12
weeks post-baseline) and FES condition (two levels; with and
without the assistance of FES) was used to check for statistically
significant effects on gait kinematics and walking test performance.
The effects of longer-term FES use on patient-reported outcomes
and step count were explored via repeated measures ANOVA with
time (three levels, baseline, 6 weeks post-baseline, 12 weeks post-
baseline) serving as the only within subject factor. Equivalent non-
parametric tests were used for data not found to be normally
distributed. A first order autoregressive correlation structure was
used in the repeated measures ANOVA model. Where appropri-
ate, we reported the interaction effects and all main effects (p-
values) for the within-subject factors of time and condition.
Statistical significance was accepted for p-values,0.05. SPSS v 19
was used for statistical analysis.
Cohen’s effect size d for the training effect at 12 weeks and the
total orthotic effect were calculated to inform the sample size for
Habitual FES to Treat Foot-Drop for People with MS
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future, appropriately powered, larger scale trials. Effect sizes were
defined to be medium for values for Cohen’s d of more than 0.3
but less than 0.5, good for values of 0.5 and greater but less than
0.8, and large for values of 0.8 and greater [29].
The measurements at the assessment four weeks before baseline
and the baseline assessment were used to calculate the Standard
Error of Measurement and the Minimally Detectable Change.
The standard error of measurement (SEM) was calculated from
the standard deviation at baseline and the reliability coefficient:
SEM=SD * !(1-r), where r is the reliability coefficient
(Cronbach’s alpha) and the Minimally Detectable Change
(MDC) was derived from the SEM: MDC=1.96*!2 * SEM.
The number of participants exceeding the MDC for both the
training effect and total orthotic effect were counted.
Results
During the recruitment period (August 2011–April 2013) twenty
three people with MS presented with foot-drop and were judged
suitable by a specialist physiotherapist for FES to the dorsiflexors.
Of those twenty-three, fifteen wished to be fitted with FES and
were invited to participate in the study. Eleven gave informed
consent and underwent the first assessment (see CONSORT
diagram Fig. 1). However, two participants did not return after
their first visit as they did not wish to continue with FES therapy,
resulting in nine participants being available for follow-up and
who were included in the data analysis. Participant characteristics
are shown in Table 1. There were no adverse events reported.
Gait kinematics
Gait kinematics are shown in Table 2. Peak dorsiflexion in
swing (p= 0.006) and stride length (p= 0.049) were significantly
improved in the FES assisted condition compared to no FES,
indicating a direct orthotic effect. Over the 12 week period, a
significant effect of time, indicating an improvement from baseline
was observed for both stride length (p = 0.045) and walking speed
(p = 0.046) and just failed to reach significance for ankle angle at
Initial Contact (IC) (p = 0.082). Cohen’s effect size ‘d’ for a training
effect ranged from 0.22 for peak knee flexion in swing to 0.78 for
ankle angle at IC, indicating improved, more normal gait
kinematics. Compared to the baseline assessment without FES,
the following gait kinematics in the trials with FES had good effect
sizes indicating improvement at the 12 week assessment (total
orthotic effect): ankle angle at IC and peak dorsiflexion in swing
(Cohen’s d.1.0), stride length and walking speed (d = 0.70 and
d= 0.80), knee flexion in swing (d= 0.36) and hip range of motion
(d = 0.45).
Walking performance
Table 3 shows the results of the walking performance tests and
gait characteristics with and without FES over the three
assessments. Both the 10 meter and the 2 minute walking
performance tests showed improved values for the FES assisted
condition compared to without FES for all three assessments. A
statistically significant direct orthotic effect was found both for the
2 minute walk test (p = 0.002) and the 10 meter walk test
(p = 0.006). No statistically significant effect of time was found
for any of the walking performance outcomes. Average training
effects at 12 weeks were 8.2% for the 10 meter walk test and 4.7%
for the 2 minute walk test (Cohen’s d,0.29). The difference
between the RPE at the end of the 2 minute test compared to the
first lap was on average 1.2 points lower at 12 weeks compared to
baseline (Cohen’s d=20.86).
The total orthotic effect, the change in walking speed with FES
at 12 weeks relative to the walking speed without FES at baseline
was 12.1% (Cohen’s d=20.41) for the 10 meter walk test and
9.8% (Cohen’s d= 0.42) for 2 minute test. A large effect size
(Cohen’s d =20.95) for total orthotic gain was found for the
dRPE indicating a lower increase in RPE over 2 minutes in the
FES assisted condition after 12 weeks compared to without FES at
baseline.
Self-reported measures and objective physical activity
Table 4 shows the self-reported measures and daily step count
over the three assessments. There were no statistically significant
effects of time for any of the measures except for the MS walking
scale in the FES group. Effect sizes of the change between 12
weeks and baseline were all small (d,0.3). Interestingly, the MS
walking scale was significantly lower, i.e. improved at 6 weeks
compared to at baseline (p = 0.034) but was back to the baseline
level at 12 weeks.
Patient outcomes exceeding Minimally Detectable
Change (MDC)
The number of participants exceeding the MDC for both the
training and total orthotic effect at the 12 week assessment is
provided in Table 5. The MDC was derived from participants’
baseline and baseline – 4 week scores. Interestingly, although the
Figure 1. CONSORT diagram.
doi:10.1371/journal.pone.0103368.g001
Table 1. Participant characteristics, means (standard
deviation).
Male/female 2/7
Age (years) 53(9) range 35–64
RM/PP/SP 4/4/1
Body Height (m) 1.67(0.09)
Body Mass (kg) 70(14)
Body Mass Index (kg/m2) 24.8(2.1)
Walking aid/no walking aid during
walking tests
1/8
RM: Relapse-Remitting, PP: primary progressive, SP: secondary progressive.
doi:10.1371/journal.pone.0103368.t001
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majority of participants showed improvements exceeding the
MDC between 12 weeks and baseline for the 10 meter walk test
tests, improvements exceeding the MDC in gait kinematics and
self-reported measures were less common. Figure 2 illustrates the
individual participant changes scores in relation to the MDC for
the MS walking scale.
Discussion
The primary aim of this pilot study was to investigate the
training and total orthotic effects on gait kinematics and walking
performance tests after using FES to treat foot-drop for a period of
12 weeks. We also investigated whether self-reported measures of
walking performance, impact of MS on daily living, fatigue and
habitual physical activity improve as a result of using FES over a
period of 12 weeks.
A statistically significant improvement over time was observed
for stride length and walking speed (p,0.05). At 12 weeks the
ankle angle at initial contact without the assistance of FES showed
a shift towards more dorsiflexion of 2.6 degrees (Cohen’s d= 0.78)
compared to unassisted gait at baseline, indicating a trend towards
a training effect.
Good to excellent effect sizes were found for the total orthotic
effect for ankle angle at IC (3.4u, d = 1.0) and dorsiflexion in swing
(2.9u, d = 1.3). No previous studies on FES have recorded the total
orthotic effects on gait kinematics in people with MS. However, a
study with children with CP [30] reported a similar total orthotic
gain of 3.5u. Winter [31] showed that a change in joint angle of as
little as 2u could significantly alter foot clearance, indicating a
possible clinical relevance of the improvements in ankle kinematics
found in the current study.
This pilot study showed no statistically significant effect of time
for the walking performance tests. Small average training effects
on walking performance of 4.7% and 8.1% (Cohen’s d,0.3) were
found for the 2 minute and 10 meter walking tests respectively.
Interestingly, after 12 weeks of FES use, participants showed a
trend (Cohen’s d.0.8) towards a smaller increase in RPE from the
start to end of the two minute walk test with dRPE. This may
reflect a lower perception of effort of walking when walking with
FES assistance and also a possible carry-over effect when walking
without FES after 12 weeks of FES use.
The average training effects on the walking performance tests
observed in the current study are similar to those reported in
earlier studies. Stein et al [9] observed for their progressive group
(all but one consisting of pwMS). who used the WalkAide for three
months, improvements of 9.1% for the 4 minute walk test and
5.3% for the 10 meter walk test. A recently published study by
Taylor et al [13] assessed the effects of different combinations of
FES for foot drop, FES to the hip extensors and home exercises.
After 6 weeks of using FES for foot-drop, they reported that
participants showed (a non significant) 9.7% increase in the
walking speed over 10 meters which was slightly more than in the
current study.
However, a lack of training effect or even a slight decrease in
walking performance over longer time periods for pwMS has been
reported by several authors. In a study by Barrett et al [16]
comparing the effects of exercise training and FES for a period of
18 weeks in a group of people with Secondary Progressive MS, the
average walking speed over 10 meters decreased from 0.79 m/s to
0.73 m/s in the FES group. However, again, this decrease did not
reach statistical significance. The results of Barrett’s study agree
with earlier work by Taylor et al [11] who also observed a (non
statistically significant) decrease in walking speed (0.03 m/s) andT
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increase in Physiological Cost Index (0.13) after four and half
months of FES use in pwMS.
Over an even longer time period, Stein et al [9] reported that at
the 11 months assessment point, a group of people with
progressive diseases (mainly MS) did not show the same degree
of continued improvement as seen in a group of people with non-
progressive diseases, but nonetheless a small training effect (5.6%)
was maintained for 10 m test. The influence of the progressive
nature of MS was also highlighted in the results of the study by
Taylor et al in 2013 [12]. Unlike those recovering from a stroke,
the people with MS in this recent study did not show a mean
training effect over a period of 16.5 months. However, 12 out of
35 patients did achieve a meaningful increase in speed of walking
defined as more than 0.05 m/s [32] while 10 patients showed a
decrease in speed of walking of 0.05 m/s or more.
The finding that some participants showed improvements whilst
others deteriorated, resulting in an average neutral effect, was also
observed in our study. Although no statistical significant effect of
time was found for the 10 meter test, based on the MDC data
derived from the results in this study, individual participant
responses indicated that after 12 weeks 5 out of the 9 participants
showed an improvement in walking speed without FES over
10 meters.
The participants in our study did not show any changes in self-
reported walking performance (MSWS-12), impact of MS on daily
living (MSIS29), fatigue or objective physical activity after 12
weeks of using FES. Interestingly, there was significant improve-
ment in the MSWS at 6 weeks (average of 6 points), at which point
the MSIS29 (average of 9 points) and the daily step count (average
of 539 steps) also showed trends towards improvement. However,
these trends towards improvement were not maintained at 12
weeks (Fig. 2). A statistically significant improvement in both
components of the MSIS29 after 6 weeks of FES was also found in
the study by Taylor et al [12] although the improvement in the
total score, observed by these authors, was considerably higher
(25.6 points) than in the current study. A possible explanation for
the difference between our results and that of Taylor et al. are the
higher baseline values for the latter study (87.6 vs. 73.0 for the total
score). It is possible that people whose function is more affected by
MS may subjectively experience more benefit of FES compared to
those less affected.
A limitation of pilot studies such as ours and others [13,14] is
the lack of power to detect statistically significant differences for
some of the outcome measures. For example, based on our results,
future appropriately powered studies would require at least 24
participants in the trial to detect a statistically significant (p,0.05)
training effect for dorsiflexion in swing, and 51 participants for a
training effect on walking speed over 10 meters, both based on
80% power and paired t-test data. However, it can be argued that
for a progressive disease such as MS with a large variability among
participants in their disease progression, a frequency analysis using
minimally detectable changes may be just as informative as
median or mean group changes.
Table 5 showed that although the majority of participants
improved their walking performance both over 10 meters and
2 minutes, this could not be explained by a similar number of
participants exceeding the MDC for ankle kinematics. Similarly
only a few participants reported an improved walking perfor-
mance, a lower impact of MS, and a decrease in fatigue and none
increased their step count more than the MDC. A lack of a
relationship between objective walking performance and self-
report measures was also observed by Barrett et al [33] who found
that an improvement in objective walking performance due to FES
to correct dropped foot was not correlated with perceived Quality
of Life after 18 weeks of FES use.
There are several possible explanations for these findings.
Firstly, the lack of a correlation could be a result of the clinimetric
properties of the outcome measures. Gait kinematics are not only
influenced by day to day variability of the walking performance of
the participant, but also by test retest marker placement errors,
even with strict marker placement protocols [34]. Self-reported
measures on the other hand may not be responsive enough to
Table 4. Mean (std) of the self-reported measures and daily step count, p-values for the effect of time (ANOVA unless otherwise
stated) are also included.
Baseline 24 baseline 6 weeks 12 weeks Cohen’s d P time
MSIS29* 74.0(23.6) 73.0(21.2) 67.3(21.3) 72.3(22.4) 20.03 0.130
MSWS*¥ 75.4(8.2) 70.0(11.8) 61.5(11.7) 69.4(8.9) 20.04 0.034
FSS* 4.8(1.5) 4.8(1.6) 4.9(0.9) 5.1(0.8) 0.22 0.261¥
Step count 5353(2872) 5394(1836) 5933(2290) 5758(2406) 0.20 0.363
¥ = Friedman’s ANOVA.
* =A higher value indicates a higher impact of MS.
doi:10.1371/journal.pone.0103368.t004
Figure 2. Individual change scores from baseline for MSWS at 6
and 12 weeks. Broken line: Levels of Minimally Detectable Change
(MDC) for negative change (indicates improvement) and positive
change (indicates deterioration).
doi:10.1371/journal.pone.0103368.g002
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detect small changes in perceived walking ability, quality of life or
fatigue. Secondly, an improvement in walking performance on the
10 m and 2 minute test may not only result from improved gait
kinematics but also due to an increased confidence and reduced
mental and physical effort of walking when using FES to correct
foot-drop. Finally, it is also possible that walking over a smooth
floor in a gait laboratory may have limited ecological validity to
translate to every day walking performance, and thus impact on
self-report measures. Further studies exploring the impact of FES
to treat foot-drop are warranted to further explore these
hypotheses.
Conclusions
To our knowledge this is the first study investigating the
medium-to-long-term effects of FES to correct foot-drop on gait
kinematics and self-reported walking ability, fatigue and habitual
physical activity in pwMS. This pilot study showed that this type of
intervention over a 12 week period appears to offer the potential to
improve ankle joint kinematics and improve walking speed over
10 meters and 2 minutes FES compared to the baseline assess-
ment without the assistance of FES. However, although these
improved outcomes were directionally similar, it is important to
note that improvements in gait kinematics and walking perfor-
mance were not clearly related. Furthermore, the observed
improvements in walking speed and gait kinematics, were not
reflected in patient reports of walking performance, impact of MS
on daily life, fatigue or objectively measured habitual physical
activity (as measured by step count). Further studies into more
ADL related measures of walking ability such walking for a longer
duration or outdoor walking may provide further insight in the
relationship between objectively measured walking performance
and perceived walking ability, impact of MS in daily living and
fatigue.
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